The prevalence of diabetes is increasing. Improved glucose control is fundamental to reduce both long-term micro-and macrovascular complications and short-term complications, such as diabetic ketoacidosis and severe hypoglycaemia. Frequent blood glucose monitoring is an essential part of diabetes management. However, almost all available blood glucose monitoring devices are invasive. This determines a reduced patient compliance, which in turn reflects negatively on glucose control. Therefore, there is a need to develop non-invasive glucose monitoring devices that will reduce the need of invasive procedures, thus increasing patient compliance and consequently improving quality of life and health of patients with diabetes.
optimal glucose control is important in reducing the risk of significant long-term microvascular (nephropathy, retinopathy) and macrovascular (cardiovascular disease) complications, as well as neuropathy.
Intensive insulin therapy and frequent blood glucose determinations are recommended to achieve glucose objectives in Type 1 diabetes patients.
1 Self-monitoring of blood glucose (SMBG) is performed by obtaining a capillary blood sample by means of a lancing device and then measuring the blood glucose employing a glucose meter.
The obtained result represents the blood glucose at the moment when the blood was drawn. This method provides an accurate determination the glucose levels; however, significant oscillations in blood glucose may be ignored, hindering the achievement of an optimal glycaemic control. 2 Furthermore, SMBG entails a significant number of daily punctures that many patients find uncomfortable and painful.
Continuous glucose monitoring (CGM) systems measure interstitial fluid glucose levels providing continuous information reflecting blood glucose levels. This continuous monitoring may recognise glucose oscillations that may otherwise remain unidentified with SMBG alone. Currently, the use of CGM is not common practice. 3 CGM is considered to be particularly useful for children (to reduce the often very high number of finger punctures in this group), for patients with poorly controlled diabetes, for pregnant women in whom tight glucose control is essential with respect to the outcome of pregnancy and for patients with hypoglycaemia unawareness (to prevent dangerous episodes of hypoglycaemia). 4, 5 A recent meta-analysis by Langendam et al. 4 shows that there is limited evidence for the effectiveness of real-time CGM (RT-CGM) on glycaemic control. However the reduction in HbA1c levels seems to be related to actual CGM use. After 12 months, those patients who used their CGM frequently had a significantly lower HbA1c level compared who patients who showed low or no sensor usage. 4 Furthermore, a recent consensus statement from the European Society for Pediatric Endocrinology, the Pediatric Endocrine Society and the International Society for Pediatric and Adolescent Diabetes declared that the use of RT-CGM may be appropriate for motivated children and youth of all ages provided that appropriate support personnel are available. 6 CGM therefore provides detailed information on glucose oscillations and trends. This allows patients to manage their diabetes more successfully. Several CGM systems are commercially available.
Two types of CGM systems can be identified according to the way information is delivered:
• Retrospective systems that measure the glucose concentration during a certain time span: the information is stored in a monitor and can be downloaded in a second moment.
• RT systems that continuously provide the actual interstitial glucose concentration and trend on a display.
CGM devices can be further classified into three categories: invasive, minimally invasive and non-invasive. Sensor placement/invasiveness depends on the its transduction mechanism. 14 This may ultimately lead to an increased risk of hypoand hyperglycaemia. Consequently, patients should be adequately trained on the use of CGM devices to avoid misinterpretation of continuous data.
While CGM requires proper training and time from physicians to interpret and analyse the data, it has been shown to be advantageous to patients by increasing their time spent in euglycaemic range. This can improve the patient's glycaemic control and can ultimately help reduce HbA1c. [15] [16] [17] Despite the benefit of multiple information provided by RT-CGM (i.e.
glucose trends and trend alerts, alerts for hypo-/hyperglycaemia, predictive alerts) it has not been embraced. Several reasons such as complexity, inaccuracy, inappropriate expectations, invasiveness, cost, pain, discomfort, risk of infection and interference with daily activities remain significant drawbacks. 18 These matters have hampered motivation to begin CGM and frequency of CGM use. Since clinical studies have shown a linear relationship between increased use of CGM and lowered HbA1c, lack of adoption and infrequent use are of significant concern and have spurred the necessity to develop less invasive technology.
Minimally Invasive Continuous Glucose Monitoring
Minimally invasive technology has been investigated in the past. The
GlucoWatch was a near-continuous RT-CGM device shaped like a watch with hypo-and hyperglycaemia alerts. The glucose level was measured and displayed every 10 minutes for up to 13 hours. 19 This technology seemed very appealing as there was no transdermal pricking. However, drawbacks were related to time lag between values, a cumbersome calibration procedure and poor accuracy in hypoglycaemic range. This device has therefore been removed from the market because of the development of more satisfying diabetes-management devices. 
Non-invasive Continuous Glucose Monitoring
There is a need to minimise discomfort and the potential risk of infection from fluid-withdrawing probes penetrating the skin along with avoiding the foreign body response that otherwise can compromise accuracy. The lack of invasiveness would allow greater tolerability and wearability, therefore increasing sensor adoption rate and long-term adherence. This would ultimately favour reduction in HbA1c and glucose variability and consequently a significant decrease in diabetes acute and chronic complications.
Non-invasive devices include: transdermal sensors that pass near-infrared (NIR) light across the stratum corneum to detect glucose concentrations under optical approaches, and external assays of body fluids (i.e. saliva, tears, breath) using various optical and electrochemical detection methods.
However, current non-invasive technologies have significant drawbacks mainly related to inaccuracies due to variable skin properties: pigmentation, body water content, hydration, non-specificity to glucose, temperature, poor correlation between blood glucose and glucose in body fluids (see Table 1 ). 7 Multisensor systems are currently being studied as they may be able to achieve a broader biophysical characterisation of the multiple physical and chemical properties of the analysed tissue -mainly the skin -and improve accuracy under variable conditions. 21 The development of non-invasive CGM devices faces crucial challenges represented by the improvement of signal-to-noise ratio and sensitivity, development of wearable devices, development of procedures for precise blood glucose determination and reducing the time taken for glucose measurements. The signal-to-noise ratio and the sensibility of non-invasive CGM devices can be improved by employing next-generation transducers and methods that can perform parallel monitoring of multiple parameters.
Retrieved sensor data can be further improved using digital filters and data treatment methods.
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Beyond Hardware CGM implementation is still suboptimal because of several factors.
The first concern is related to the uncertainty of CGM data because glucose readings suffer from interference by noise that confounds their interpretation. Noise may result in false oscillations that could trigger artificial hypo-or hyperglycaemic alerts. Some denoising algorithms have been developed to resolve this potentially dangerous phenomenon.
22-24
Another concern is accuracy. CGM data present delays that are mainly secondary to the blood-to-interstitium glucose transport and sensor processing time. Furthermore, systematic under-or overestimations due to calibration problems may add to this inaccuracy. 25 Several strategies have been proposed to compensate the inaccuracy and to enhance CGM data calibration. [26] [27] [28] [29] [30] Furthermore, CGM sensors report glucose value with a lag time with respect to blood glucose.
Therefore, there is the necessity of generating predictive hypo-and hyperglycaemic alerts by applying short-term glucose prediction algorithms.
This would allow the patient to take action before an approaching glucose excursion. Newer insulin pump predictive shutoff algorithms are shown to be able to prevent hypoglycaemic events, especially during sleep. 27 Finally, blood glucose meters are calibrated based on a laboratory reference, but current CGM devices are calibrated against a blood glucose meter, putting them one step behind a laboratory value. To overcome these problems, so-called 'smart CGMs' are being developed reduce uncertainty and inaccuracy of sensor collected data by applying RT algorithms. cost-effectiveness, comfort, patient safety) but also by the way the stream of data is processed algorithmically. This will ultimately result in increased accuracy, biocompatibility and wearability, consequently leading to improved user compliance, health and quality of life. Furthermore there still are no universally accepted guidelines regarding how to apply diabetes management decisions using CGM trend information. 34, 35 Although technological improvements are crucial for the success of CGM, one must not neglect that any device, no matter how advanced, must be driven and assessed by a human mind. A trained care team and individualised treatment are necessary for effective blood glucose control in each patient. Adequate patient education on CGM data interpretation is fundamental to guarantee a successful outcome. ■ GlucoWatch © G2 Biographer Wrist skin Advantages: CE and FDA approved; takes into account the skin temperature and perspiration fluctuations; alarm and trend indicators for rapid changes in glucose readings; event marking, data download, software analysis and data storage capacity Disadvantages: Expensive; requires 2-3 hour warm-up period, calibration using a standard blood glucose meter and replacement of disposable pad every 12 h; difficulty in calibration; inaccuracy due to subject's movement, exercising, sweating or rapid temperature changes; cannot be used in water; skin irritation was the main drawback; it shuts down automatically in cases of sweating, works better at high glucose levels and does not reliably detect hypoglycaemia
Bioimpedence spectroscopy Biovotion AG (Solianis Monitoring AG; Pendragon)
GlucoTrack TM Wrist skin Advantages: CE approved; data downloading via USB, data analysis, software, data-storage capacity and long-lasting battery; alerts for rapid changes in glucose concentration and hypoglycaemia; self-correction for changes in impedance due to variations in temperature. Disadvantages: Glucose readings vary in individuals; requires additional calibration for differences in skin and underlying tissues among individuals; difficulty in calibration; Pendra tape needs to be changed every 24 h; device needs to be reattached at the same spot where it was calibrated followed by 1-hour equilibrium time; poor correlation of only 35 % with glucose meters; Clark Error Grid Analysis indicated 4.3 % readings in error zone E; patient must rest for 60 min for equilibration before the reading; it cannot be used in many subjects whose skin types and basic skin impedances are unsuitable for the device; poor accuracy in post-marketing validation study 
